3M Collaborates with IDRI on Vaccine Adjuvants
3M Drug Delivery Systems (St. Paul, MN) has signed a non-exclusive license agreement with the Infectious Disease Research Institute (IDRI, Seattle, WA) in support of vaccine research for humanitarian efforts in developing countries.
3M Drug Delivery Systems (St. Paul, MN) has signed a non-exclusive license agreement with the Infectious Disease Research Institute (IDRI, Seattle, WA) in support of vaccine research for humanitarian efforts in developing countries. Under the agreement, 3M will donate its patented toll-like receptor (TLR) immune response modifier compounds.
3M’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by IDRI to research new vaccines. Vaccine adjuvants are known to help boost the effectiveness of a vaccine.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
